Retatrutide: The Triple Receptor Agonist Redefining Metabolic Research

Published by PPTDS | Research Use Only

The peptide research landscape has shifted considerably over the past decade. First came the GLP-1 receptor agonists. Then the dual GIP/GLP-1 compounds. Now, a third generation is emerging and the compound drawing the most attention from the research community is retatrutide peptide (LY3437943), a unimolecular triple agonist targeting three distinct hormone receptors simultaneously.

This post covers what the published science says about how retatrutide works, what phase 2 data has shown, and where the research currently stands.

What Is Retatrutide?

Retatrutide (LY3437943) is an investigational acylated peptide developed by Eli Lilly and Company. As a retatrutide peptide, it is structurally a single molecule conjugated to a fatty diacid moiety, a design that confers a half-life of approximately six days and supports once-weekly subcutaneous administration.

What distinguishes it from earlier incretin-based compounds is its triagonist architecture: it simultaneously activates the GLP-1, GIP, and glucagon receptors (GLP-1R, GIPR, and GCGR). No approved therapeutic has achieved this combination in a single molecule at clinical scale.

For research purposes only. Retatrutide is an investigational compound. It is not approved for human therapeutic use in any jurisdiction.

How Does Retatrutide Work?

Understanding the mechanism requires looking at each receptor arm individually, then considering what happens when all three are engaged at once.

GLP-1 Receptor Agonism

GLP-1R activation is the best-characterised of the three pathways. It drives glucose-dependent insulin secretion, slows gastric emptying, and reduces appetite through central satiety signalling. This is the same pathway targeted by semaglutide and, in part, tirzepatide.

Relative to the endogenous GLP-1 ligand, retatrutide activates GLP-1R at 0.4× potency — a deliberately modulated level, as full GLP-1R potency at this scale could produce excessive gastrointestinal burden.

GIP Receptor Agonism

Retatrutide is markedly potent at GIPR, approximately 8.9× more potent than the endogenous GIP ligand. GIP receptor activation amplifies postprandial insulin release and is thought to play a role in adipose tissue metabolism and central appetite regulation. The contribution of GIPR agonism to weight outcomes remains an active area of mechanistic investigation.

Glucagon Receptor Agonism

This is the mechanistically novel element. Glucagon receptor activation increases hepatic glucose output under fasting conditions and drives thermogenesis via brown adipose tissue. In the context of a triagonist, this is balanced against the insulin-sensitising effects of GLP-1R and GIPR engagement. The net result, as evidenced in preclinical models, is an increase in energy expenditure that is additive to the appetite-suppressing effects of the other two arms.

Cryo-EM structural analysis published in 2024 confirmed the binding geometry of retatrutide at all three receptor complexes, providing mechanistic validation of its multiplexed pharmacological action (PMC11255275).

Key Takeaways from Phase 2 Research

Obesity - NEJM Phase 2 Trial (2023)

The landmark phase 2 obesity trial, published in the New England Journal of Medicine, enrolled 338 adults with a BMI ≥30. Participants received once-weekly subcutaneous retatrutide at doses of 1 mg, 4 mg, 8 mg, or 12 mg, or placebo, over 48 weeks.

At 48 weeks, mean body weight reductions were:

  • 1 mg: −8.7%
  • 4 mg: −17.1%
  • 8 mg: −22.8%
  • 12 mg: −24.2%
  • Placebo: −2.1%

At the 12 mg dose, 100% of participants achieved ≥5% weight reduction, 93% achieved ≥10%, and 83% achieved ≥15%. These figures represent a meaningful step beyond those observed with dual agonists in comparable timeframes.

Reference: Jastreboff AM et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. N Engl J Med. 2023. PubMed → 37352118

Type 2 Diabetes - Lancet Phase 2 Trial (2023)

A separate phase 2 trial published in The Lancet investigated retatrutide in 281 participants with type 2 diabetes. The compound demonstrated clinically meaningful reductions in HbA1c alongside substantial body weight reduction, with a safety profile consistent with that of approved GLP-1-based therapies.

The trial also noted that retatrutide’s gastrointestinal tolerability was manageable at lower starting doses, with adverse events occurring primarily during the escalation phase.

Reference: Rosenstock J et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes. Lancet. 2023. PubMed → 37352119

Liver Fat & MASLD - Nature Medicine (2024)

A phase 2a substudy published in Nature Medicine examined participants from the obesity trial who had metabolic dysfunction-associated steatotic liver disease (MASLD) with ≥10% baseline liver fat. Results at 24 weeks showed mean relative reductions in liver fat of:

  • 1 mg: −42.9%
  • 4 mg: −57.0%
  • 8 mg: −81.4%
  • 12 mg: −82.4%
  • Placebo: +0.3%

At the highest doses, more than 90% of participants with NAFLD achieved normalisation of liver fat, an outcome researchers attributed in part to glucagon receptor agonism promoting hepatic lipid oxidation via pathways distinct from GLP-1 and GIP.

Reference: Abdelmalek MF et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease. Nat Med. 2024;30:2037–2048. PubMed → 38858523

Structural Biology - Cryo-EM Binding Confirmation (2024)

Researchers used cryo-electron microscopy to resolve the binding of retatrutide across all three receptor complexes simultaneously. The structural data confirmed differential potency at each receptor and provided a mechanistic basis for the compound’s pharmacological profile including that it is more potent than endogenous GIP at GIPR while modulating GLP-1R and GCGR at sub-endogenous levels.

Reference: Structural insights into the triple agonism at GLP-1R, GIPR and GCGR manifested by retatrutide. PMC. 2024. PMC11255275

Cardiovascular Markers

The NEJM phase 2 data also noted reductions in LDL cholesterol of approximately 20% in the retatrutide groups, an effect researchers attributed to glucagon receptor agonism and its downstream effects on PCSK9 degradation. This area remains under active investigation in ongoing trials.

Phase 3 Status

As of 2025, retatrutide is progressing through phase 3 clinical trials across three indications: obesity, type 2 diabetes, and non-alcoholic fatty liver disease/MASLD. Regulatory submissions are anticipated following completion of these trials.

Reference: Doggrell SA. The “Weight” for a New Agent Is Almost Over: A Commentary on the Novel Triagonist Retatrutide for Obesity. PubMed. 2024. PubMed → 39507873

Retatrutide in the Research Setting

For laboratories investigating incretin receptor pharmacology, triagonist mechanisms, or metabolic disease models, the reta peptide represents a structurally and mechanistically distinct tool compound relative to earlier generation GLP-1 analogues or dual agonists.

Its differential receptor potency profile; high GIPR, modulated GLP-1R, and attenuated GCGR  offers a model for studying the relative contribution of each receptor arm to metabolic outcomes, a question that remains unresolved in the literature.

References

  1. Jastreboff AM et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. N Engl J Med. 2023. https://pubmed.ncbi.nlm.nih.gov/37352118/
  2. Rosenstock J et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes. Lancet. 2023. https://pubmed.ncbi.nlm.nih.gov/37352119/
  3. Abdelmalek MF et al. Triple hormone receptor agonist retatrutide for MASLD. Nat Med. 2024;30:2037–2048. https://pubmed.ncbi.nlm.nih.gov/38858523/
  4. Structural insights into the triple agonism at GLP-1R, GIPR and GCGR manifested by retatrutide. PMC. 2024. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11255275/
  5. Coskun T et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist. Cell Metab. 2022;34(9):1234–1247. https://pubmed.ncbi.nlm.nih.gov/36030764/
  6. Doggrell SA. The “Weight” for a New Agent Is Almost Over. PubMed. 2024. https://pubmed.ncbi.nlm.nih.gov/39507873/

Supplied for laboratory research only. Not for human or veterinary use. Updated: May 2026.

Back to blog